Publishing company Elsevier is revising its policies and procedures for partnering with pharmaceutical companies to create custom publications in response to recent media attention over a fake journal, called the __Australasian Journal of Bone and Joint Medicine__ (__AJBJM__), created by the company and paid for by Merck. Elsevier provided __The Scientist__ with the names of additional custom publications produced by the company's Australia office from 2000-2005, that an Elsevier spokesperson admitted "should not have been called 'journals'." According to Elsevier, these other publications differed from __AJBJM__ in that they were not sponsored by a single corporation, but were instead paid for by selling "clearly-marked" advertisements purchased by several pharmaceutical companies. Like __AJBJM__, the additional publications did not contain original research. Sponsors had some editorial input, but not as much as Merck had over __AJBJM__, the spokesperson said. "We don't have any indication that any one of our advertisers or sponsors...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?